RA Capital Management L.P. acquired a new stake in ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,155,964 shares of the biopharmaceutical company's stock, valued at approximately $28,980,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank N A MO acquired a new position in shares of ChemoCentryx in the 4th quarter valued at about $37,000. Lazard Asset Management LLC acquired a new position in ChemoCentryx during the 4th quarter worth approximately $60,000. Prospera Financial Services Inc acquired a new position in ChemoCentryx during the 1st quarter worth approximately $46,000. Point72 Hong Kong Ltd acquired a new position in ChemoCentryx during the 4th quarter worth approximately $115,000. Finally, Commerce Bank acquired a new position in ChemoCentryx during the 4th quarter worth approximately $219,000. 81.09% of the stock is owned by institutional investors and hedge funds.
Get ChemoCentryx alerts:ChemoCentryx Stock Performance
Shares of CCXI stock traded down $0.05 during trading on Tuesday, hitting $51.45. The company's stock had a trading volume of 21,283 shares, compared to its average volume of 1,904,635. The company has a market cap of $3.67 billion, a PE ratio of -27.23 and a beta of 1.25. The company has a current ratio of 4.54, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average of $38.94 and a 200-day moving average of $28.58. ChemoCentryx, Inc. has a 52 week low of $14.95 and a 52 week high of $51.78.
Wall Street Analysts Forecast Growth
CCXI has been the topic of a number of research reports. Canaccord Genuity Group initiated coverage on ChemoCentryx in a research note on Thursday, August 4th. They set a "buy" rating and a $81.00 price target on the stock. StockNews.com raised ChemoCentryx from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. HC Wainwright lowered ChemoCentryx from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $101.00 to $52.00 in a report on Friday, August 5th. Canaccord Genuity Group lowered ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price objective for the company. in a report on Friday, August 5th. Finally, Stifel Nicolaus lowered ChemoCentryx from a "buy" rating to a "hold" rating in a report on Wednesday, August 10th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, ChemoCentryx has an average rating of "Hold" and an average target price of $65.25.Insider Activity
In other ChemoCentryx news, CFO Susan M. Kanaya sold 19,898 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $50.95, for a total transaction of $1,013,803.10. Following the completion of the transaction, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,652,601.15. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other ChemoCentryx news, CFO Susan M. Kanaya sold 19,898 shares of the stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $50.95, for a total transaction of $1,013,803.10. Following the sale, the chief financial officer now owns 91,317 shares in the company, valued at $4,652,601.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James L. Tyree sold 10,000 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $50.22, for a total value of $502,200.00. Following the sale, the director now owns 9,138 shares in the company, valued at approximately $458,910.36. The disclosure for this sale can be found here. Insiders sold a total of 213,760 shares of company stock valued at $10,749,838 over the last three months. Corporate insiders own 8.30% of the company's stock.
ChemoCentryx Profile
(Get Rating)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Featured Stories
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.